联合检测SCC-Ag和CA125对预测中晚期宫颈癌放疗后复发转移的价值

Value of combined detection of SCC-Ag and CA125 in predicting recurrence and metastasis of locally advanced cervical cancer after radiotherapy

目的 探讨通过联合检测鳞状上皮癌抗原（SCC-Ag）及肿瘤相关糖类抗原CA125在中晚期宫颈鳞状细胞癌治疗前后的水平,预测肿瘤复发和转移的价值.方法 采集246例中晚期宫颈癌患者治疗前后的血清样本,用电化学发光免疫测定法测定SCC-Ag和CA125水平,并进行分析.结果 中晚期宫颈癌血清SCC-Ag、CA125的水平随肿瘤分期升高而升高（P〈0.05）,治疗后SCC-Ag、CA125的水平逐渐下降.多因素分析表明血清SCC-Ag、CA125水平在治疗后下降至2.0ng/ml和35U/ml以下,其复发转移率明显下降,差异有统计学意义（P〈0.01）.结论 治疗后SCC-Ag、CA125下降的程度可以作为预测治疗后复发和转移的依据.

Objective TO determine the value of detection of squam0us cell carcinoma antigen （SCC-Ag） and tumor-associated carbohydrate antigen 125 （CA125） in predicting recurrence and metastasis in patients with locally advanced cervical squamous ceil carcinoma. Methods Serum samples of 246 patients with locally advanced cervical squamous cell cancer were collected before and after treatment. Levels of SCC-Ag and CA125 were measured by electrochemical luminescence immunoassay. Results Serum levels of SCC-Ag and CA125 increased along with increased tumor stage （P 〈 0.05）. Decreased levels of SCC-Ag and CA125 were observed after treatment. Recurrence and metastasis rate was significantly lower in patients with SCC-Ag ≤ 2ng/ml and CA125 ≤ 35U/ml after treatment than those with higher SCC-Ag and CA125 （P= 0.000）. Conclusion Measurement of serum SCC-Ag and CA125 levels after treatment may be used for predicting tumor recurrence and metastasis in patients with locally advanced cervical squamous cell carcinoma.